17β-HSD Inhibitor

17β-HSD Inhibitors (150):

Cat. No.	Product Name	Effect	Purity

HY-19903

ASP-9521	Inhibitor	98.0%
ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC₅₀ of 11 nM for human AKR1C3.

HY-107379

AKR1C3-IN-1	Inhibitor	98.21%
AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC₅₀ of 13 nM.

HY-148814

BI-3231	Inhibitor	99.83%
BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.

HY-138557

AKR1C3-IN-4	Inhibitor	99.77%
AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.

HY-152189

S19-1035	Inhibitor	99.93%
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC₅₀ value of 3.04 nM. S19-1035 can be used for the research of tumor.

HY-164221B

Rapirosiran sodium scrambled negative control	Inhibitor
Rapirosiran sodium scrambled negative control is the sequence scrambled negative control of Rapirosiran sodium.

HY-183280

17β-HSD10/CDK5-IN-1	Inhibitor
17β-HSD10/CDK5-IN-1 is a poent dual 17β-HSD10 and CDK5 inhibitor with IC₅₀s of 2.44 and 0.26 μM for 17β-HSD10 and CDK5, respectively. 17β-HSD10/CDK5-IN-1 reduces ROS accumulation, attenuates pathological Tau phosphorylation, reduces Aβ plaque deposition, and ameliorates cognitive deficits in Alzheimer's mice. 17β-HSD10/CDK5-IN-1 can be used for the research of Alzheimer's disease.

HY-182028

17β-HSD10-IN-4	Inhibitor
17β-HSD10-IN-4 is a selective brain-penetrant 17β-HSD10 inhibitor with an IC₅₀ of 6.33 μM. 17β-HSD10-IN-4 forms key interactions with the 17β-HSD10 catalytic triad to functionally inhibit the enzyme, without altering its protein levels. 17β-HSD10-IN-4 restores mitochondrial function, reduces ROS levels, increases ATP production, and suppresses cytochrome c release. 17β-HSD10-IN-4 attenuates CDK5/p25 activation, reduces Tau hyperphosphorylation, Aβ plaque load and restores brain-derived neurotrophic factor levels. 17β-HSD10-IN-4 improves cognitive function.17β-HSD10-IN-4 can be used for the research of Alzheimer's disease.

HY-145433

17β-HSD1-IN-1	Inhibitor	99.79%
17β-HSD1-IN-1 (Compound 1) is a highly selective 17β-HSD1 inhibitor with IC₅₀s of 5.6 and 3155 nM for 17β-HSD1 and 17β-HSD2, respectively. 17β-HSD1-IN-1 can be used for the research of non-small cell lung cancer (NSCLC).

HY-155035

S07-1066	Inhibitor	99.48%
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells.

HY-W005186

6-Bromocoumarin	Inhibitor	98.51%
6-Bromocoumarin (compound 34) is a potential anti-bacterial agent, with no inhibition against 17β-HSD1. 6-Bromocoumarin exhibtis affinity for α and β estrogen receptors.

HY-155534

17β-HSD10-IN-1	Inhibitor
17β-HSD10-IN-1 (compound 9) is an orally active inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with blood-brain permeability. 17β-HSD10-IN-1 doesn't result additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects.

HY-159525

Linustedastatum	Inhibitor	98.10%
Linustedastatum (Linustedastat; FOR-6219) is an orally active hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor. Linustedastatum can be used for the study of endometriosis.

HY-103394

TC HSD 21	Inhibitor	99.0%
TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC₅₀ of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.

HY-164221A

Rapirosiran sodium	Inhibitor
Rapirosiran sodium is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran sodium can be used for the study of Non-alcoholic steatohepatitis.

HY-149040

Odafosfamide	Inhibitor	99.06%
Odafosfamide ((S)-OBI-3424) is a highly selective prodrug bis-alkylating agent activated by aldehyde-keto reductase 1C3 (AKR1C3(). Odafosfamide is highly cytotoxic to cell lines with high AKR1C3 expression. Odafosfamide exhibits antitumor activity in a variety of tumors with high AKR1C3 expression (such as liver cancer, non-small cell lung cancer, and leukemia). Odafosfamide can be used in cancer research.

HY-156735

HSD17B13-IN-2	Inhibitor	99.72%
HSD17B13-IN-2 is an HSD17B13 inhibitor with human IC₅₀ values of 0.18 μM (with β-estradiol as substrate) and 0.25 μM (with Leukotriene B4 as substrate), and it exhibits selectivity for human HSD17B11. HSD17B13-IN-2 binds to the active site of HSD17B13 in an NAD⁺-dependent manner, interacts with the bound NAD⁺ cofactor, and stabilizes human HSD17B13 protein to prevent its aggregation. HSD17B13-IN-2 reduces the conversion of β-estradiol to estrone in cellular assays. HSD17B13-IN-2 can be used in studies related to nonalcoholic fatty liver disease.

HY-128145

HSD17B13-IN-41	Inhibitor
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.

HY-157627

HSD17B13-IN-9	Inhibitor	99.92%
HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-161212

HSD17B13-IN-8	Inhibitor	99.97%
HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC₅₀ values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

Name
Email *

	Sorry, but the email address you supplied was invalid.